11 METHOD OF ESTIMATING RISK OF THE EXPRESSION OF SIDE EFFECT CAUSED BY THE ADMINISTRATION OF COMPOUND METABOLIZED EITHER PER SE OR AS ITS METABOLIC INTERMEDIATE BY UGT1A1 ENZYME

摘要

It is an object of the present invention to provide a method for predicting adverse side effects of administration of irinotecan. Also provided is a method of reducing the side effects of administration of irinotecan. (Polymorphism due to the difference in the number of repeats of the TA repeating sequence in the promoter region of the T1A1 gene and two polymorphisms (base at position 211 and base at position 686) due to single base substitution in exon 1 are analyzed. Based on the results of the analysis, we predict the risk of adverse events associated with administration of irinotecan. In addition, the dose of irinotecan is set for each patient according to the risk of side effects, and the side effects of administration of irinotecan are reduced.